Seven $1 billion-plus drugs seen reaching market in 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Merck (MRK) Tops Q4 EPS by 2c
February 3, 2016 6:45 AM ESTMerck (NYSE: MRK) reported Q4 EPS of $0.93, $0.02 better than the analyst estimate of $0.91. Revenue for the quarter came in at $10.22 billion versus the consensus estimate of $10.35 billion.
The past year was one of considerable progress and execution for Merck, said Kenneth C. Frazier, chairman and chief executive officer, Merck. Im excited by the near-term opportunities, as we continue launching important new products like ZEPATIER and KEYTRUDA while augmenting and advancing our... More
